BioPharma Dive: AstraZeneca, Merck make case for PARP's place in pancreatic cancer
Rating: 5.0 Stars
- This is article is easy to read and provides an accurate portrayal of this study.
- There is a short discussion of other drugs and results that are from the relate class of drugs. This provides a well-balanced perspective.
- Outside sources are used.
- It is factually correct and scientific terminology is used appropriately.
MedPageToday: POLO will change practice in pancreatic cancer
Rating: 4.0 Stars
- This is a well written article that portrays the novelty of this study well.
- There are multiple sources cite and the scientific infromation is accurately conveyed.
- There is not a discussion of the field; this article is somewhat imbalanced. There is no critical evaluation of the research presented in this study.
CNN: Pancreatic cancer therapy sheds light on the disease's ties to BRCA mutation
Rating: 3.0 Stars
- This is an easy to read informational article focused on this study.
- It states that there was a reduced risk of disease progression (true) or death (not true).
- Stats cited are not those published but may reflect preliminary numbers.
Bloomberg Weekly: AstraZeneca's Lynparza slows spread of rare pancreatic cancer
Rating: 2.0 Stars
- The headline states that Lynparza slows spread of rare pancreatic cancer.
- This is not accurate. While disease free-progression is delayed, it is not clear that increased metastates is slowed as opposed to growth of the primary tumor. Furthermore, while pancreatic cancer is not common, it is not rare. The title and lede imply that this is a rare form of pancreatic cancer, while it is the most common form of pancreatic cancer.
- The article states that fewer than 7% of people with pancreatic cancer have BRCA mutations which is inaccurate. This study observed 7.5% of people with pancreatic cancer had BRCA mutations. Other studies have seen rates above 10% in some populations.